Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

NCT01976572 | Completed Phase 1 Results

• 1 other identifier: MCI-196-E17
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective is to assess the effects of colestilan on the pharmacokinetic profile of candesartan cilexetil when administered at the same time as, 1 hour before, and 3 hours after the first daily dose of colestilan administered at doses of 5 g three times daily compared to administration of candesartan cilexetil alone, in healthy subjects.

Conditions

Hyperphosphatemia; Chronic Kidney Disease

Keywords

CKD Stage V; dialysis

Outcome Measures

Primary Outcomes (2)

• AUC0-t of Candesartan

  Area under the plasma concentration-time curve from time zero up to the last quantifiable time-point

  0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose

• Cmax of Candesartan

  Maximum observed plasma concentration

  0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose

Secondary Outcomes (2)

• Tmax

  0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose

• T1/2

  0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose

Study Arms (4)

Candesartan alone

PLACEBO COMPARATOR

Single dose of 16 mg candesartan was administered orally on Day 1.

Drug: candesartan

T0hr

ACTIVE COMPARATOR

Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-0 of 3 dosing time-points means the single dose of candesartan was administered at the same time relative to the first daily dose of colestilan.

Drug: colestilan; Drug: candesartan

T-1hr

ACTIVE COMPARATOR

Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-1 of 3 dosing time-points means the single dose of candesartan was administered at 1 hour before relative to the first daily dose of colestilan.

Drug: colestilan; Drug: candesartan

T+3hr

ACTIVE COMPARATOR

Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T+3 of 3 dosing time-points means the single dose of candesartan was administered at 3 hour after relative to the first daily dose of colestilan.

Drug: colestilan; Drug: candesartan

Interventions

colestilan DRUG

Also known as: BindRen

T+3hr; T-1hr; T0hr

candesartan DRUG

Candesartan alone; T+3hr; T-1hr; T0hr

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able to provide written informed consent to participate in this study, after reading the participant information sheet and informed consent form (ICF), and after having the opportunity to discuss the study with the Investigator or designee.
• Caucasian male subjects aged 18 to 50 years inclusive.
• A body mass index (BMI) between 18.0 and 32.0 kg/m2, both inclusive.
• Healthy subjects, free from any clinically significant illness or disease as determined by their medical history, physical examination, electrocardiogram (ECG), vital signs, biochemistry, haematology, coagulation, urinalysis, and serology.
• Male subjects, and their partners, agree to use contraception throughout the study duration. Male subjects must use 1 barrier method of contraception and spermicide during the trial, and for 3 months after the last dose of study drug. Male subjects with female partners of child-bearing potential must also agree to use an additional highly effective method of contraception. They must use a condom, and their female partners must use an additional method of contraception (such as cap or diaphragm), unless the subject or his partner has been sterilised, in which case, male subjects must use a condom and spermicide.

You may not qualify if:

• Subjects who have had a clinically significant illness within 4 weeks of the start of dose administration, as determined by the Investigator based on abnormal medical history, physical findings, or laboratory values at Screening or Baseline.
• Unable to swallow colestilan tablets, current and/or history of dysphagia.
• Current or any history of any of the following gastrointestinal (GI) diseases: intestinal obstruction, chronic or severe constipation, subileus, ileus, intestinal stenosis, intestinal diverticulosis and/or diverticulitis, colitis, GI ulcers, recent major GI surgery, peritonitis, GI bleeding, gastritis, haemorrhoids, or any other severe GI disease.
• Current or any history of biliary obstruction, cholestasis, or severe hepatic impairment.
• Current or history of seizure disorders.
• Current or history of Vitamin K deficiency.
• Subjects who have any clinically significant allergic disease (excluding non-active hayfever) as determined by the Investigator.
• Current or recent history (in the last 2 years) of abuse or addiction (tobacco, alcohol, drugs or substances), or weekly alcohol intake of more than 21 units, or a positive alcohol breath test or urine drug screen at Screening or Baseline. One unit is equivalent to a ½ pint (280 mL) of beer, 1 measure (25 mL) of spirits or 1 small glass (125 mL) of wine.
• Treatment with any drugs or herbal or dietary supplements known to be inhibitors of cytochrome P450 (CYP) 3A4, CYP2C9 or P-glycoprotein, 7 days before dosing and inducers of CYP3A4, CYP2C9, or P-glycoprotein 14 days before dosing.
• Treatment with H2 antagonist and/or proton pump inhibitors, during 4 weeks before dosing.
• Subjects with a history of hypotension or hyperkalaemia, or a postural drop of systolic blood pressure ≥20 mmHg at Screening.

Sponsors & Collaborators

• Tanabe Pharma Corporation: lead

Study Sites (1)

Covance Clinical Research Unit Ltd.

Leeds, Springfield House Hyde Street, United Kingdom

Location

MeSH Terms

Conditions

Hyperphosphatemia; Renal Insufficiency, Chronic

Interventions

cholebine; candesartan

Condition Hierarchy (Ancestors)

Phosphorus Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Clinical Trials, Information Desk
• Organization: Tanabe Pharma Corporation

cti-inq-ml.JP@ml.tanabe-pharma.com

Study Officials

• Jim Bush, Dr

  Covance

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 30, 2013
• First Posted: November 6, 2013
• Study Start: October 1, 2013
• Primary Completion: January 1, 2014
• Study Completion: January 1, 2014
• Last Updated: January 7, 2026
• Results First Posted: October 30, 2015

Record last verified: 2025-12

Locations

GB (1)